13-cis retinoic acid as continuation therapy in children with advanced neuroblastoma in complete or good partial remission

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title
Study objectives	Not provided at time of registration
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Solid tumour of childhood
Intervention	Initial therapy followed by either: 1. Continuation Therapy: Thirteen-cis-retinoic acid 2. Control: Placebo
Intervention type	Other
Primary outcome measure(s)	Not provided at time of registration
Key secondary outcome measure(s)	Not provided at time of registration
Completion date	30/03/1997

Participant type(s)	Patient
Age group	Child
Sex
Key inclusion criteria	1. Stage III or IV neuroblastoma 2. In complete or good partial remission following initial therapy
Key exclusion criteria	Not provided at time of registration
Date of first enrolment	01/03/1995
Date of final enrolment	30/03/1997

UKCCCR Register Co-ordinator

London
NW1 2DA
United Kingdom

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary
IPD sharing plan

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2000		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes